ImpactWayv™ Launches Social Media Platform Focused on Social Good
15.6.2021 16:00:00 EEST | Business Wire | Press release
ImpactWayv, Inc. today announced the public launch of its pioneering social media platform, ImpactWayv™, which is now available to download on the Apple App Store. The new platform’s focus is to connect people, businesses and philanthropy for social good.
Designed to be a healthier and more meaningful alternative to major social networking platforms, ImpactWayv was created to drive collective impact across causes and communities. The platform operates as an entirely new kind of digital ecosystem, enabling users to effect, engage in and share social impact on a global scale.
Users of ImpactWayv will be able to connect and interact with each other through each of its core components, including:
- Public and private personal networks and content feeds to engage with and create impact.
- The “Impact Market” – a public exchange of transparent impact profiles of businesses and nonprofits for all to compare, follow, engage with and directly support.
- “Wayvs” (social impact causes, topics, trends and broader issue areas) – an organizing framework for purpose-driven content and information across the platform.
“ImpactWayv is democratizing social impact for all,” said Dan Rubino, Co-Founder, Chairman and Chief Executive Officer of ImpactWayv, Inc. “Finally, there is a purpose-built social media platform that gives consumers, brands, businesses and nonprofits a way to explore, create, engage and transact across all categories of daily life, with more meaning, more purpose and more goodwill.”
Engagement on the platform is driven by dozens of Wayvs™ ranging across social impact cause areas and covering various topics relating to the interplay of business, philanthropy and individual effort to drive social good. Some examples include Climate Action; Diversity, Equity and Inclusion (DE&I); Corporate Social Responsibility (CSR); Human Rights; Public Health; Environmental, Social and Governance (ESG); Voter Registration; and Renewable Energy. Wayvs facilitate and encourage user discoverability and engagement across the platform. Users tap them to find relevant impact discussions and initiatives, as well as like-minded individuals, companies and nonprofits that share their commitment to the causes they care about.
“An unprecedented interest in social action has been building globally for some time, further accelerated and focused by recent events,” said George Dolatly, Co-Founder and President of ImpactWayv, Inc. “People need a way to explore and express their values. Businesses need to use their resources and influence to make things better. And nonprofits need to leverage their missions for maximum effectiveness. ImpactWayv meets this unique moment in time by linking people and organizations around the world on a deeper level.”
To catalyze user engagement, ImpactWayv also created a groundbreaking tool to measure a user’s impact on their digital community, through the platform’s signature “Impact” metric, which tracks a user’s positive “ripple effect” across the platform, in real time.
“Our ambition at ImpactWayv is to disrupt and transform the worlds of business and philanthropy through technology,” said Benji Bernstein, Co-Founder and Chief Technology Officer of ImpactWayv, Inc. “Through our extraordinary blend of seasoned leaders and trailblazers in the worlds of corporate purpose, philanthropy and technology, we believe we have created a powerful business model that will advance universal social good.”
ImpactWayv is now available for free download on the Apple App Store and will be available on Google Play and other non-iOS devices later this year. Companies and nonprofits are also invited to contact ImpactWayv to become a member of the platform, which will enable them to claim their profile, initiate an engagement strategy on ImpactWayv and become a “Featured Organization” on the platform.
About ImpactWayv, Inc.
ImpactWayv, Inc. is a social impact media and technology company, consisting of thought leaders and doers from across the business, nonprofit and technology sectors. ImpactWayv was created to disrupt and transform the worlds of business and philanthropy through technology – to advance universal social good. For more information, please visit: www.impactwayv.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005331/en/
Contact information
Media
Jonathan Younger
214-259-3426
jonathan.younger@ketchum.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
